Taft Pharmaceutical Litigation partner Andrew Alul was quoted in the Bloomberg BNA article “High Court Won’t Review Case on Diagnostic Method Patents” on June 11, 2018. The article appeared in the Pharmaceutical Law & Industry Report and discussed the recent Supreme Court decision not to hear a case brought by Cleveland Clinic concerning what diagnostic tests are eligible for patent. Read the article here.
Alul focuses his practice on intellectual property litigation and counseling, particularly pharmaceutical drug patent litigation and regulatory litigation involving the U.S. Food and Drug Administration (FDA). He has extensive experience litigating cases brought under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act for pharmaceutical products and under the Administrative Procedures Act.